Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
暂无分享，去创建一个
M. Andreeff | H. Kantarjian | G. Garcia-Manero | J. Cortes | S. Verstovsek | M. Keating | S. O'brien | F. Giles | Deborah A. Thomas | S. Faderl | W. Wierda | A. Ferrajoli | B. Pro | C. Koller | M. Beran | Ngoc Tran | D. Thomas